Voyager Therapeutics : Reports Fourth Quarter and Full Year 2021 Financial and Operating Results - Form 8-K

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results


License option agreement with Novartis for target-specific access... | March 8, 2022

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Al Sandrock Jr ,Neurocrine Biosciences ,Sanofi Genzyme ,Michael Higgins ,Scott Santiamo ,Al Sandrock ,Andrew Funderburk ,Alfredw Sandrock Jr ,Robin Swartz ,Product Services ,Voyager Therapeutics Inc ,Board Executive Committee ,Antibody Program Highlights Advancement Of Rich Early ,Health Care Conference ,Nasdaq ,Novartis ,Exchange Commission ,Pfizer ,Pfizer Inc ,Committee Of The Board ,Voyager Therapeutics Reports Fourth Quarter ,Full Year ,Executive Committee ,Specific License Option Agreement ,Novartis Expands Applications ,Tropism Redirection ,Cell Type Specific Expression ,Pfizer Supports ,Cardiac Applications ,Portfolio Planned ,Spring Medical ,Preclinical Data ,Program Highlights Advancement ,Rich Early Stage ,Leadership Appointments Add ,Glenn Pierce ,Senior Vice President ,Global Business Operations ,Disease Patient ,Senior Director ,Upcoming Investor ,Annual Health Care Conference ,Voyager Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Operations Items ,Nc Stock Exchange ,News ,Information ,Press Release ,Oyager ,Herapeutics ,Reports ,Fourth ,Quarter ,End ,Bull ,Ear ,021 ,Financial ,Operating ,License ,Option ,Agreement ,Ith ,Or Vygr Us92915b1061 ,